Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The food and beverage sector is currently at a low position in terms of fundamentals and valuations, presenting significant investment opportunities as the peak season approaches [4][12] - The food and beverage index experienced a decline of 1.4% from January 19 to January 23, ranking 25th among 28 sectors, underperforming the CSI 300 by approximately 0.8 percentage points [12][13] - The Consumer Price Index (CPI) rose by 0.8% year-on-year in December 2025, indicating a mild recovery trend, and has returned to relatively high levels compared to recent years [4][12] - The upcoming Spring Festival is expected to catalyze performance in the sector, with strong demand for consumer goods, particularly in the snack segment, which continues to show upward momentum [4][12] Summary by Sections Weekly Insights - The food and beverage sector is positioned for a recovery as it approaches the peak season, with a notable increase in demand expected during the Spring Festival [4][12] - The sector's current valuation aligns with policy support aimed at boosting consumption, providing a safety margin for investments [4][12] Market Performance - The food and beverage index's performance was weaker than the broader market, with specific sub-sectors like snacks (+6.1%), processed foods (+4.9%), and baked goods (+4.3%) showing relative strength [12][13] Upstream Data - Recent data indicates a decline in some upstream raw material prices, with whole milk powder prices down 13.5% year-on-year as of January 20, 2026 [19][21] - The price of fresh milk was reported at 3.03 CNY per kilogram, reflecting a year-on-year decrease of 2.6% [19][21] Alcohol Industry Data - In December 2025, the production of liquor (65-degree equivalent) decreased by 12.1% year-on-year, with a total production of 354.9 million liters for the year [42][43] Recommended Investment Targets - Key investment opportunities identified include raw milk/dairy products, the snack sector, and the restaurant supply chain, with specific companies highlighted for their growth potential [4][5][12]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The pharmaceutical and biotechnology sector is expected to experience a cyclical recovery in raw material prices for animal health products in 2026, following a prolonged decline due to oversupply and weak downstream demand [5][49] - Heparin and iodine contrast agent raw materials are currently at the bottom of their price cycles, with heparin prices declining sharply in Q4 2023 due to market pressures, while iodine prices have seen a recent recovery driven by strong demand from other industries [6][51] Summary by Sections Industry Trends - The pharmaceutical and biotechnology sector saw a decline of 0.39% in the third week of January 2026, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th among 31 sub-industries [7][58] - The offline pharmacy segment experienced the highest increase, rising by 9.66%, while the medical research outsourcing segment faced the largest decline, dropping by 3.96% [7][61] Price Trends - The average price of florfenicol has decreased from the range of 400-700 RMB/kg to a recent range of 100-200 RMB/kg, indicating a significant drop to historical lows [5][47] - Heparin API prices are stabilizing, while iodine raw material prices are expected to rise in 2025 due to previous supply constraints [51][55] Recommended Stocks - Monthly recommended stocks include WuXi AppTec, 3SBio, and CSPC Pharmaceutical Group, among others [8] - Weekly recommended stocks include Kanglong Chemical, WuXi AppTec, and Aopumai [8]

Investment Rating - The industry investment rating is "Overweight" (maintained) [2] Core Insights - The electronic industry index experienced a weekly change of +1.58%, with semiconductors rising by 2.7% and consumer electronics declining by 1.4% [4] - TSMC plans to build four advanced packaging facilities to enhance backend capacity, driven by strong demand for AI [6] - The AI hardware market is expected to see a surge in product launches, including OpenAI's AI audio headphones with projected shipments of 40-50 million units in the first year [5] Market Review - The semiconductor sector is witnessing a significant increase in demand, with TSMC's 3nm capacity fully booked until 2027 due to AI demand [6] - Major storage companies are entering a price increase cycle as they face unprecedented chip shortages, with Micron indicating that its HBM orders for 2026 are already filled [5] - The import value of key semiconductor equipment in China reached 15.5 billion yuan in December 2025, marking a 244% month-on-month increase [6] Industry Developments - AI infrastructure is rapidly developing, with domestic GPU manufacturers accelerating their self-sufficiency processes [5] - Companies like SK Hynix and Kioxia have reported that their chip and flash memory production capacities for 2026 are already sold out, exacerbating NAND supply pressures [5] - The Nasdaq index saw a slight decline of 0.06% this week, while notable gains were observed in companies like SanDisk (+14.56%) and AMD (+12.01%) [4]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The pharmaceutical and biotechnology sector is expected to experience a cyclical recovery in raw material prices for animal health products in 2026, following a prolonged decline due to oversupply and weak downstream demand [5][49] - Heparin and iodine contrast agent raw materials are currently at the bottom of their price cycles, with heparin prices declining sharply in Q4 2023 due to market pressures, while iodine prices have seen a recent recovery driven by strong demand from other industries [6][51] Summary by Sections Industry Trends - The pharmaceutical and biotechnology sector saw a decline of 0.39% in the third week of January 2026, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th among 31 sub-industries [7][58] - The offline pharmacy segment experienced the highest increase, rising by 9.66%, while the medical research outsourcing segment faced the largest decline, dropping by 3.96% [7][61] Price Trends - The average price of florfenicol has decreased from the range of 400-700 RMB/kg to a recent range of 100-200 RMB/kg, indicating a significant drop to historical lows [5][47] - Heparin raw material prices have stabilized after a period of decline, while iodine raw material prices are expected to rise again in 2025 due to increased demand [51][55] Recommended Stocks - Monthly recommended stocks include WuXi AppTec, 3SBio, and CSPC Pharmaceutical Group, while weekly recommendations feature companies like Kanglong Chemical and Yao Ming He Lian [8]

Group 1 - The report indicates that the recent market adjustment does not warrant panic, as the spring rally may continue, with small-cap stocks outperforming large-cap stocks in the current environment [2][12][35] - There has been a significant net outflow from broad-based ETFs, particularly from the CSI 300 ETF, which is not seen as a signal to exit the market but rather as a healthy market behavior [3][14][20] - The report highlights that in a bullish market, changes in trading volume often trigger a style switch favoring small-cap stocks, which tend to outperform large-cap stocks when average daily trading volume increases [4][27][28] Group 2 - The investment strategy suggests maintaining a positive outlook on the market, with a focus on technology and cyclical sectors as dual drivers of growth [5][35] - Specific industry allocations are recommended, including technology sectors such as AI hardware, military, media (gaming), and cyclical sectors benefiting from PPI improvements [36][35] - The report emphasizes the importance of monitoring the changes in institutional positions within the AI sector and the transition of new themes in the first year of the 14th Five-Year Plan, such as commercial aerospace and brain-computer interfaces [5][36]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The automotive sector shows a strong performance with a 2.21% increase, outperforming the broader market [6][23] - The demand for high-end domestic passenger vehicles is exceeding expectations, with a favorable competitive landscape [7] - The commercial vehicle index has seen a significant increase of 7.38%, indicating robust growth in this segment [6] Industry News - Geely's self-developed all-solid-state battery is set to complete its first pack line by the end of the year [5][13] - Tesla has adjusted its Model S/3/X/Y and Cybertruck models, removing the standard Autopilot feature and shifting to a subscription model for FSD [5][13] - Xiaopeng Motors has expanded its global sales network to over 1,000 outlets, entering nearly 30 new markets [5][16] - The humanoid robot market is seeing significant growth, with UNITREE announcing over 5,500 units shipped in 2025, potentially leading the industry [5][17] Market Performance - The automotive sector's performance is ranked 16th among A-share industries this week, with a notable increase in the commercial vehicle and auto parts sectors [6][23] - The passenger vehicle sector's PE valuation has decreased, while commercial vehicles and auto parts have seen a 10% increase in PE valuations [10][12] Investment Recommendations - For passenger vehicles, companies like JAC Motors and Seres are recommended due to strong demand and competitive positioning [7] - In the auto parts sector, companies such as Desay SV and Zhejiang Xiantong are highlighted for their growth potential amidst improving profitability [7]

Investment Rating - The industry investment rating is "Overweight" (maintained) [2] Core Insights - The electronic industry index experienced a weekly change of +1.58%, with semiconductors rising by 2.7% and consumer electronics declining by 1.4% [4] - TSMC plans to build four advanced packaging facilities to enhance backend capacity, driven by strong demand for AI and advanced 3nm processes [6] - Major storage companies are entering a price increase cycle due to unprecedented chip shortages, with Micron and SK Hynix reporting full order books for 2026 [5] Market Review - The semiconductor sector showed a weekly increase of 2.7%, while the consumer electronics sector saw a decline of 1.4% [4] - Notable stock performances included SanDisk up 14.56%, AMD up 12.01%, and Micron up 10.17% [4] Industry Updates - AI hardware is expected to see a surge in releases, with OpenAI planning to launch AI audio headphones with projected shipments of 40-50 million units in the first year [5] - The demand for AI infrastructure is increasing, with domestic GPU manufacturers accelerating their development processes [5] - TSMC's advanced 3nm production capacity is fully booked until 2027, indicating strong market demand [6] Beneficiary Stocks - Beneficiary stocks include Huahong Semiconductor, Zhongwei Company, Jingce Electronics, and several others [6]

通信 业 2026 年 01 月 25 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -26% 0% 26% 53% 79% 106% 2025-01 2025-05 2025-09 通信 沪深300 相关研究报告 《重视硅光和 CPO 链投资机会—行 业点评报告》-2026.1.21 《台积电和谷歌表现亮眼，重视硅光 链和谷歌链—行业周报》-2026.1.18 《光、液冷、国内 AIDC 迎新变化— 行业周报》-2026.1.11 重视边际变化：卫星和国产 AI 链 蒋颖（分析师） 陈光毅（联系人） 雷星宇（联系人） jiangying@kysec.cn 证书编号：S0790523120003 chenguangyi@kysec.cn 证书编号：S0790124020006 leixingyu@kysec.cn 证书编号：S0790124040002 海内外太空建设加速，重视商业航天和卫星链 2026 年 1 月 22 日，蓝箭航天空间科技股份有限公司（简称"蓝箭航天"）科 创板 IPO 审核状态变更为"已问询" ，此次 IPO 公司拟募资 75 亿元，用于可 重复使用火箭产能提升项目、可重复使用 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights a significant price increase trend in the CCL (Copper Clad Laminate) industry, driven by rising raw material costs and strong demand from sectors such as AI and electric vehicles [5][6] - Major companies in the CCL sector have implemented multiple price hikes throughout 2025, with notable increases from leading firms like 建滔积层板 and Resonac [5][6] - The profitability of CCL manufacturers has improved significantly due to these price increases, with companies like 生益科技 reporting a substantial rise in gross margins [7] Summary by Sections Price Increase Overview - The CCL industry has experienced a global price increase trend, with key players raising prices multiple times in 2025, including a 10% increase in December [5] - Resonac announced a price hike of over 30% for its products starting in March 2026, reinforcing global price increase expectations in the CCL sector [5] Drivers of Price Increase - The primary drivers for the current price increases in the CCL industry include rising costs of core raw materials such as copper, electronic cloth, and epoxy resin [6] - Copper prices saw a cumulative increase of nearly 40% in 2025, with LME copper prices reaching $12,960 per ton [6] - The demand for high-performance epoxy resin has surged, particularly for AI servers and advanced packaging boards, contributing to the rising costs in the CCL segment [6] Profitability and Investment Recommendations - The profitability of CCL manufacturers has shown significant recovery, with 生益科技 achieving a gross margin of 26.85% in Q2 2025, reflecting a year-on-year increase [7] - The report suggests focusing on the CCL price increase cycle and AI penetration rates, recommending stocks such as 生益科技, 金安国纪, and 建滔积层板 as beneficiaries of this trend [8]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected performance that will exceed the market by over 20% [4]. Core Insights - The company forecasts a significant increase in net profit attributable to shareholders for 2025, estimated between 41 to 44 million yuan, representing a year-on-year growth of approximately 213.65% to 236.61% [1]. - The expected operating revenue for 2025 is around 362 million yuan, reflecting a year-on-year increase of about 16.77% [1]. - The company is actively investing in high-end instruments and has made progress in their smart and digital capabilities, with new products like organic element analyzers and liquid chromatography instruments gaining market recognition [2]. - The company has received multiple invention patents, enhancing its intellectual property moat and supporting future product iterations and market expansion [3]. Financial Summary - The projected financial metrics for the company are as follows: - Operating revenue (million yuan): 341 in 2023, 310 in 2024, 362 in 2025, 435 in 2026, and 499 in 2027, with a year-on-year growth of 18.7% in 2023, -9.1% in 2024, and 16.7% in 2025 [6]. - Net profit attributable to shareholders (million yuan): 45 in 2023, 13 in 2024, 43 in 2025, 53 in 2026, and 64 in 2027, with a year-on-year growth of 1.4% in 2023, -71.0% in 2024, and 225.7% in 2025 [6]. - Earnings per share (EPS): 0.53 in 2023, 0.15 in 2024, 0.50 in 2025, 0.62 in 2026, and 0.75 in 2027 [6]. - Price-to-earnings ratio (P/E): 48.3 in 2023, 166.5 in 2024, 51.1 in 2025, 41.0 in 2026, and 33.9 in 2027 [6].